Cervical Cancer: Regiment With New Drug Triapine Provides Both Significant Reduction in Cancer Disease and Cancer Control
ScienceDaily (Feb. 9, 2010) — Researchers at the Ireland Cancer Center of University Hospitals (UH) Case Medical Center, have published new findings that may lead to a new standard of care for patients with locally advanced cervical cancer.
Published in the February issue of Clinical Cancer Research, the phase one study found that a new chemotherapy...
A drug to treat the seventh most common cancer in Europe has been accepted for review by the European Medicines Agency (EMEA).
Advanced gastric cancer medication S-1 was validated for use with cisplatin for Taiho Pharmaceutical Company, Ltd.
Gastric cancer affects more than twice as many men as women in Europe, and most sufferers are aged between 50 and 70. It is the sixth most common cause of cancer death, and...
Medical News Today
Article Date: 09 Dec 2009 - 2:00 PST
Researchers in the US have developed and tested a new platinum compound that appears to be more effective at destroying cancer tumors than cisplatin, a commonly used FDA-approved drug that is administered by itself or with other drugs to treat mostly advanced bladder, ovarian, testicular and other cancers.
The study is to be published in this week's issue of the Proceedings of the National Academy of Sciences...
The National Institute for Health and Clinical Excellence (NICE) has today published final guidance recommending the use of topotecan in combination with cisplatin as a treatment option for women with recurrent or stage IVB cervical cancer who have not previously received cisplatin.
Women who have previously received cisplatin and are currently being treated with topotecan in combination with cisplatin for recurrent and stage...
Medical News Today
Article Date: 23 Oct 2009 - 3:00 PDT
Cancer patients don't have time to waste, yet many must endure a tedious process of elimination as physicians try several different treatments until identifying the one that is most effective against their particular type of tumor. Now researchers at the University of Virginia Health System have developed a breakthrough method that could one day eliminate this trial and error approach to treating many cancers.
